Use of triptorelin in dosage of 11.25 as preoperative preparation in patients with symptomatic fibroids
Abstract
Objective. To study the change in uterus volume and fibroid volume, the resistance index and pulse index in the uterine arteries after administration of triptorelin in a dosage of 11.25 mg before a planned myomectomy or operation by Osada. Materials and methods. This study included 28 patients with uterine fibroids and adenomyosis. Seven of these were excluded from the study prior to closure. As preoperative preparation, all patients received a triptorelin 11.25. Taken into account the volume of the uterus and the fibroid before administration and each month prior to surgery. Furthermore, it was compared the resistance index and pulse index in uterine arteries. Results. The results of this study showed that the volume of uterine fibroids and uterus significantly reduced by treatment with Diphereline 11.25. Fibroid size was reduced by an average of 68.3 mm3 (p = 0.014) and the volume of the uterus by 97.3 mm3 (p = 0.039), and in addition the blood flow indicators were significantly changed: the resistance index changed by 0.87 (p = 0.01) and the pulsation index by 0.43 (p = 0.08) in the uterine arteries. These results confirm the effectiveness of usage of Diphereline 11.25 as preoperative preparation before performing myomectomy to reduce blood loss and perioperative injuries.
About the Authors
N. N. Rukhlyada
Research Institute for Emergency Medicine n.a. I. I. Dzhanelidze
Russian Federation
Russian Federation
K. Y. Krylov
Research Institute for Emergency Medicine n.a. I. I. Dzhanelidze
Russian Federation
Russian Federation
References
1. Сивова Е. Н., Пашов А. И., Букреев А. В., Фокина А. П. Некоторые вопросы этиологии патогенеза пролиферативных процессов эндометрия. Сибирское медицинское обозрение. 2015; 4: 37-40.
2. Ашрафян Л. А., Киселев В. И., Муйжнек Е. Л. Патогенетическая провилактика рака репродуктивных органов. М.: Молодая гвардия; 2009.
3. Donnez J., Tatarchuk T. F., Bouchard P., Puscasiu L., Zakharenko N. F. et. al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012; 366 (5): 409^20.doi:10.1056/NEJMoa1103182.
4. Taran F. A., Weaver A. L., Coddington C. C., Stewart E. A. Characteristics indicating adenomyosis coexisting with leiomypmas: a case-control study Hum. Reprod. 2010; 25 (5): 1177-1182.doi:10.1093/humrep/deq034.
5. Maheshwari A., Gurunath S., Fatima S. et. al. Adenomyosis and subfertility: a systematic review of prevalence, diagnosis, treatment and fertility ouycomes. Hum Reprod Update. 2012; 18 (4): 374-392.doi:10.1093/humupd/ dms006.
6. Лебедев В. А., Пашков В. М. Лечение хронической железодефицитной анемии у больных с миомой и аденомиозом. Трудный пациент. 2008; 10 (6): 27-30.
7. Bajekal N, Li TC. Fibroids, infertility and pregnancy wastage. Hum. Reprod. Update. 2000; 6:614-620. [PubMed: 11129696]
8. Kurjak A, Zalud I. Uterine masses. In: Kurjak, ed. Transvaginal Color Doppler. Carnforth, UK: Parthenon Publishing, 1991: 123.
9. Kalir T, Wu H, Gordon RE, et al. Morphometric and electron microscopic analyses of the effect of gonadotropinreleasing hormone agonist treatment on arteriole size in uterine leiomyomas. Arch Pathol Lab Med 2000; 124: 1295-8.
10. Вихляева Е.М., Паллади Г. А. Патогенез, клиника и лечение миомы матки.- Кишинев. Штиница: - 1982.- 300 с.
11. Савицкий Г. А., Савицкий А. Г. Миома матки (проблемы патогенеза и патогенетической терапии) - СПб: ЭЛБИ-СПб, 2000, С. 90-139.
12. В. И. Кулаков и др, Применение препарата аГнРГ Диферелина в клинике бесплодия. Акушерство и гинекология № 4, 2002, стр. 65-68.
13. Тихомиров А. Л. Агонисты гонадотропных релизинг-гормонов в лечении миомы матки // РМЖ. 2010. №.4. С. 188.
14. Fallicori M. D., Hall D. A., Loughlin J. S. et all // Amer. J. Obstet. Gynecol.- 1983.- Vol. 147.- P. 626-737.
15. Laparoscopic myomectomy fertility results / Dubuisson J. B., Chapron C., Fauconnier A., et al. // Acad. Sci.-2001.- Vol. 943.-P. 269-275.
16. Uterine leiomyomata and sterility: therapy with gonadotropin-releasing hormone agonists and leiomyomectomy / Kuhlmann M., Gartner A., Schindler E.- M. et al. // Gynaecol. Endocrinol.-1997.-Vol. 11, № 3.-P. 169-175.
17. F. Hoellen Therapeutic drugs in the treatment of symptomatic uterine fibroids. Expert Opin. Pharmacother. 2013, 14 (15).
18. T. Reshef. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Human Reproduction Update, Vol. 20, N2, pp. 194-216, 2014.
19. Инструкция по применению препарата Диферелин, Ипсен Фарма.
20. В.Е. Балан Ведение пациенток с сочетанной патологией матки. Эффективная фармакотерапия 55/2014. Материалы XV Всероссийского научного форума Мать и дитя.
21. MattaWH, Stabile I, ShawRW, Campbell S. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin. Fertil Steril 1988; 49:1083-1085.
22. Khan KN, Kitajima M, Hiraki K, Fujishita A, Sekine I, Ishimaru T, Masuzaki H. Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy. Hum Reprod 2010;25:642-653.
23. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev2001; CD 000547
24. Romer T. Benefit of GnRH analogue pretreatment for hysteroscopic surgery in patients with bleeding disorders.Gynecol Obstet Invest 1998;45(Suppl 1):12-20; discussion 1, 35.
Review
For citations:
Rukhlyada N.N., Krylov K.Y. Use of triptorelin in dosage of 11.25 as preoperative preparation in patients with symptomatic fibroids. Medical alphabet. 2017;1(3):16-19. (In Russ.)
Views:
539
Email this article 